



Published in final edited form as:

*Pharmacol Res.* 2018 March ; 129: 515–525. doi:10.1016/j.phrs.2017.11.036.

## Functional histamine H<sub>3</sub> and adenosine A<sub>2A</sub> receptor heteromers in recombinant cells and rat striatum

Ricardo Márquez-Gómez<sup>a</sup>, Meridith T. Robins<sup>c</sup>, Citlaly Gutiérrez-Rodelo<sup>b</sup>, Juan-Manuel Arias<sup>d</sup>, Jesús-Alberto Olivares-Reyes<sup>b</sup>, Richard M. van Rijn<sup>c</sup>, and José-Antonio Arias-Montaña<sup>a</sup>

<sup>a</sup>Departamentos de Fisiología, Biofísica y Neurociencias, Av. IPN 2508, Zacatenco, 73063 Ciudad de México, México

<sup>b</sup>Departamentos de Bioquímica, Cinvestav-IPN, Av. IPN 2508, Zacatenco, 73063 Ciudad de México, México

<sup>c</sup>Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA

<sup>d</sup>Programa de Neurociencias-UIICSE, Facultad de Estudios Superiores Iztacala, UNAM, Av. de los Barrios 1, Los Reyes Iztacala, 54090 Estado de México, México

### Abstract

In the striatum, histamine H<sub>3</sub> receptors (H<sub>3</sub>Rs) are co-expressed with adenosine A<sub>2A</sub> receptors (A<sub>2A</sub>Rs) in the cortico-striatal glutamatergic afferents and the GABAergic medium-sized spiny neurons that originate from the indirect pathway of the basal ganglia. This location allows H<sub>3</sub>Rs and A<sub>2A</sub>Rs to regulate the striatal GABAergic and glutamatergic transmission. However, whether these receptors can physically interact has not yet been assessed. To test this hypothesis, a heteromer-selective *in vitro* assay was used to detect functional complementation between a chimeric A<sub>2A</sub>R<sub>302</sub>-Gα<sub>qi4</sub> and wild-type H<sub>3</sub>Rs in transfected HEK-293 cells. H<sub>3</sub>R activation with the agonist RAMH resulted in Ca<sup>2+</sup> mobilization (pEC<sub>50</sub> 7.31 ± 0.23; maximal stimulation, E<sub>max</sub> 449 ± 25% of basal) indicative of receptor heterodimerization. Functional H<sub>3</sub>R-A<sub>2A</sub>R heteromers were confirmed by co-immunoprecipitation and observations of differential cAMP signaling when both receptors were co-expressed in the same cell. In membranes from rat striatal synaptosomes, H<sub>3</sub>R activation decreased A<sub>2A</sub>R affinity for the agonist CGS-21680 (pK<sub>i</sub> values 8.10 ± 0.04 and 7.70 ± 0.04). Moreover, H<sub>3</sub>Rs and A<sub>2A</sub>Rs co-immunoprecipitated in protein extracts from striatal synaptosomes. These results support the existence of a H<sub>3</sub>R-A<sub>2A</sub>R heteromer with possible physiological implications for the modulation of the intra-striatal transmission.

---

Corresponding author: Ricardo Márquez-Gómez M. Sc., Departamento de Fisiología, Biofísica y Neurociencias, Cinvestav-IPN, Av. IPN 2508, Zacatenco, 07360, Ciudad de México, México, Tel. (+5255) 5747 5706, ricardo.marquez3@gmail.com.

#### Author contributions

R. M.-G., R. v. R. and J.-A. A.-M. designed the study; R. M.-G., C. G.-R., J.-M. A. and M. T. R. performed the experiments; R. M.-G., J.-A. O.-R., R. v. R. and J.-A. A.-M. performed data analysis. R. M.-G., R. v. R. and J.-A. A.-M. wrote the manuscript. All authors revised and approved the manuscript.

#### Conflicts of interest

The authors disclose no conflict of interest.

## Keywords

Adenosine A<sub>2A</sub> receptor; histamine H<sub>3</sub> receptor; striatum; GPCR heterodimers; basal ganglia

---

## 1. Introduction

The actions of histamine in the periphery on airway constriction, inflammation and gastric acid secretion are well known, whereas its function in the Central Nervous System (CNS) is not yet fully understood. In mammals, histamine actions are mediated by four (H<sub>1</sub>R-H<sub>4</sub>R) G protein-coupled receptors (GPCRs), of which the H<sub>3</sub> receptor (H<sub>3</sub>R) displays the highest expression in the brain. In the CNS, histamine is released from the terminals and dendrites of neurons located in the hypothalamic tuberomammillary nucleus, from where they innervate most of the CNS, including nuclei belonging to the basal ganglia, a subcortical group of structures intimately related to the control of motor behavior (Panula and Nuutinen, 2013; Panula *et al.*, 2015).

The striatum is the main input nucleus of the basal ganglia and integrates motor and sensory information. The primary striatal afferents are glutamatergic axons originating from neurons located in the cerebral cortex and thalamus, and dopaminergic axons of substantia nigra pars compacta neurons (Bolam *et al.*, 2000). In turn, the axons of the GABAergic medium-sized spiny neurons (MSNs), which account for more than 90% of the striatal neuronal population (Kemp and Powell, 1971), project to the globus pallidus and substantia nigra pars reticulata (Bolam *et al.*, 2000).

H<sub>3</sub>Rs are abundantly expressed in the striatum either as pre-synaptic auto- and hetero-receptors or as post-synaptic receptors, with the latter located on the bodies of the MSNs and GABAergic or cholinergic interneurons (Pillot *et al.*, 2002; González-Sepúlveda *et al.*, 2013; Bolam and Ellender, 2016). The understanding of the physiological role of striatal H<sub>3</sub>Rs is complicated by their ubiquitous expression and capability to engage in protein-protein interactions with other GPCRs (Nieto-Alamilla *et al.*, 2016). Of particular interest in the striatum are dopamine and adenosine receptors, which are also highly expressed. Based on the selective expression of dopamine and adenosine receptor subtypes, MSNs can be segregated into two neuronal populations. Neurons that originate the basal ganglia direct pathway (dMSNs) are identified by the expression of D<sub>1</sub>-like receptors (D<sub>1</sub>Rs) whereas the indirect pathway population (iMSNs) is formed by neurons expressing adenosine A<sub>2A</sub> receptors (A<sub>2A</sub>Rs) and D<sub>2</sub>-like receptors (D<sub>2</sub>Rs) (Schiffman *et al.*, 1991; Ferre *et al.*, 1997; Tapper *et al.*, 2004). In the striatum, H<sub>3</sub>Rs have been shown to form heterodimeric protein-protein complexes with dopamine D<sub>2</sub> and D<sub>1</sub> receptors (Ellenbroek, 2013), and heterotrimers with  $\sigma$ 1/D<sub>1</sub> receptors and NMDA/D<sub>1</sub> receptors (Moreno *et al.*, 2014; Rodríguez-Ruíz *et al.*, 2016). In turn, A<sub>2A</sub>Rs can form dimers with D<sub>2</sub>, cannabinoid CB<sub>1</sub> and adenosine A<sub>1</sub> receptors (Ciruela *et al.*, 2006; Carriba *et al.*, 2007; Hillon *et al.*, 2002) and oligomers with D<sub>2</sub> and mGlu5 glutamate receptors (Cabello *et al.*, 2009).

Both H<sub>3</sub> and A<sub>2A</sub> receptors modulate intra-striatal synaptic transmission. The activation of G $\alpha_{i/o}$ -coupled H<sub>3</sub>Rs results in inhibition of GABA, dopamine, acetylcholine and glutamate release (Doreulee *et al.*, 2001; Schlicker *et al.*, 1993; Prast *et al.*, 1999; Arias-Montaña *et al.*,

2001), whereas the activation of  $G\alpha_s$ -coupled  $A_{2A}$ Rs also inhibits GABA release but facilitates glutamatergic cortico-striatal transmission (Kirk and Richardson, 1994; Popoli *et al.*, 1995).

Either individually or through their heteromeric interactions with other GPCRs,  $A_{2A}$ Rs and  $H_3$ Rs have been proposed as targets for the treatment of basal ganglia-related disorders such as Parkinson's disease and addiction (Ferré *et al.*, 2004; Schwarzschild *et al.*, 2006; Passani and Blandina, 2011; Ellenbroek, 2013). In this work, we hypothesized that striatal  $H_3$ Rs and  $A_{2A}$ Rs can not only form heteromers with dopamine receptors, but also with each other, and that this interaction forms a unique pharmacological target that could be of potential therapeutic interest. Here we show that  $H_3$ Rs co-immunoprecipitate with  $A_{2A}$ Rs in HEK293 cells, suggestive of oligomerization. Further, we studied the physical properties of the  $A_{2A}$ R- $H_3$ R interaction by a functional complementation assay. We next showed that the  $A_{2A}$ R- $H_3$ R heteromerization has unique functional pharmacology in terms of cAMP modulation in HEK-293 cells co-expressing the receptors. Using protein extracts from striatal synaptosomes, we confirmed the presence of  $A_{2A}$ R- $H_3$ R heteromers *in vivo* by co-immunoprecipitation. Finally, we found that in the same preparation  $H_3$ R activation resulted in decreased binding affinity of  $A_{2A}$ R for the agonist CGS-21680.

A preliminary account of this work was presented in the abstract form to the European Histamine Research Society (Márquez-Gómez *et al.*, 2016) and submitted to an electronic pre-print server (Márquez-Gómez *et al.*, 2017).

## 2. Methods

### 2.1 Materials

The following drugs and reagents were purchased from Sigma Aldrich (St. Louis, MO, USA): (R)(-)- $\alpha$ -methylhistamine dihydrochloride, histamine dihydrochloride, adenosine deaminase (from bovine spleen), Percoll, quinpirole dihydrochloride. Dimaprit was from Axon MedChem (Reston, VA, USA). CGS-21680 was from Cayman Chemical (Ann Arbor, MI, USA). N- $\alpha$ -[methyl- $^3$ H]-histamine ( $78.3 \text{ Ci}\cdot\text{mmol}^{-1}$ ) and CGS-21680-[carboxyethyl- $^3$ H (N)]-( $35.2 \text{ Ci}\cdot\text{mmol}^{-1}$ ) were from Perkin Elmer (Boston, MA, USA).

### 2.2 Molecular cloning

Truncated  $A_{2A}$  or  $H_3$  receptors were generated by PCR using the primers indicated in Supplementary Table 1. After amplification and restriction with HindIII and BamHI enzymes, the truncated  $A_{2A}$  and  $H_3$  receptors were ligated to a pcDNA3.1 plasmid that contained the chimeric  $G\alpha_{qs4}$  and  $G\alpha_{qi4}$  proteins. Both  $A_{2A}$ Rs and  $H_3$ Rs (cDNA Resource Center, Bloomsberg, PA, USA) were labeled with a triple hemagglutinin tag (3xHA). To generate the 3xHA tagged receptors,  $A_{2A}$ R and the  $H_3$ R were amplified from nucleotide 377 and 458, respectively, towards their amino terminus. The 3xHA tag was amplified from a plasmid that codified for the tagged histamine  $H_4$ R (3xHA- $H_4$ R in pcDNA3.1, cDNA Resource Center). The amplified DNA fragments (3xHA- $A_{2A}$ R377/ $H_3$ R458) were then re-introduced into the pcDNA3.1- $H_3$ R or pcDNA3.1- $A_{2A}$ R backbone to obtain the tagged, full length receptors. The insertion and orientation of the amplified fragment was verified by

automated sequencing performed at FESI-UNAM (Los Reyes Iztacala, Estado de México, México).

### 2.3 Cell culture and transfection

HEK-293T cells (American Type Culture Collection, Manassas, VA, USA) were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin (50 UI/ml) and streptomycin (0.1 mg/ml) under a humidified atmosphere (5% CO<sub>2</sub> in air) at 37 °C.

For transfections, cells were seeded in 6-well plates ( $6 \times 10^5$  cells/well; up to passage 15) and incubated for 24 h at 37 °C in a 5% CO<sub>2</sub>/air mixture. The next day, 10 µl X-tremeGENE (Roche, Basilea, Switzerland) were mixed with 500 µl Optimem (Life Technologies, San Diego, CA, USA) and the mixture was incubated for 5 min at room temperature before the addition of cDNA in a 1:5 ratio with X-tremeGENE. For cAMP assays a mixture of DNA:Glosensor cAMP plasmid (1:2 ratio) was added to the Optimem/X-tremeGENE solution. When plasmids containing the A<sub>2A</sub>R or H<sub>3</sub>R were transfected alone, the amount of DNA was preserved by adding empty pcDNA3.1 vector. The transfection mixture was incubated for 20 min at room temperature and then added to the cells, which were incubated for 24 h at 37 °C under a humidified atmosphere (5% CO<sub>2</sub>/air).

For co-immunoprecipitation assays, HEK-293T cells, grown in 100-millimeter Petri dishes and at 80% confluence, were transfected using the Lipofectamine 2000 method. Briefly, a mixture of DNA/Lipofectamine 2000 (1:2 ratio) was incubated for 20 min at room temperature before being added to the cells. After incubation for 5 h at 37 °C under a humidified atmosphere (5% CO<sub>2</sub>/air), the medium was replaced by high-glucose DMEM supplemented with 10% FBS and 1% antibiotic/antimycotic. Incubation continued for a further 24 h under the same condition.

### 2.4 cAMP accumulation assay

cAMP assays were performed as described in detail elsewhere (Chiang *et al.*, 2016). Briefly, HEK-293T cells transfected with 3xHA-A<sub>2A</sub>R, 3xHA-H<sub>3</sub>R or a mixture of both plasmids (1 µg each) together with Glosensor cAMP plasmid (Promega, Madison, WI, USA) were seeded in a white 384-well low-volume plate (25,000 cells/well in 7.5 µl medium) and incubated with Glo-equilibrium medium (7.5 µl, Promega). Drugs under test were added in a 5 µl volume (4x in HBSS solution) and endogenous cAMP luminescence was measured in real-time in a Flexstation 3 apparatus (Molecular Devices, Sunnyvale, CA, USA).

### 2.5 Calcium mobilization assay

HEK-293T cells transfected with 1 µg of DNA were seeded ( $2.5 \times 10^4$  cells/well) in a 384-well clear bottom black plate (25 µl-volume) and incubated for 24 h at 37 °C in a humidified 5% CO<sub>2</sub>/air atmosphere, covered with Areaseal film (Sigma, St. Louis, MO, USA). Cells were then loaded with 25 µl of the FLIPR Ca<sup>2+</sup> dye (Molecular Devices, Sunnyvale, CA, USA) and incubated for 1 h at 37 °C. Agonists were added in a 20 µl volume and calcium mobilization was measured in real-time for 2 min in a Flexstation 3 apparatus (Molecular Devices, Sunnyvale, CA, USA) and analyzed as described in detail in van Rijn *et al.* (2013).

## 2.6 Synaptosome preparation

All procedures were approved and controlled by the Cinvestav Animal Care Committee and were in accord with the rules issued by the National Institutes of Health (NIH Publications No. 8023) and the Mexican Council for Animal Care. Wistar rats (males, 250–300 g, provided by Unidad de Producción y Experimentación para Animales de Laboratorio; Cinvestav, Mexico City) were decapitated, the brain was quickly removed from the skull and the forebrain was separated and deposited on a metal plate placed on ice. The striata from 3–5 animals were dissected using forceps and the whole tissue was placed in 5 ml 0.32 M sucrose solution containing 10 mM Hepes, 1 mg/ml bovine serum albumin and 1 mM EDTA (pH 7.4 with NaOH). The tissue was homogenized using 10 strokes of a hand-held homogenizer (400 rpm), the homogenate was centrifuged (1000xg, 10 min, 4 °C) and the supernatant was pelleted at 14,000xg (12 min, 4 °C). The pellet was re-suspended in 5 ml of a Percoll solution (45 %, v:v) in Krebs-Henseleit-Ringer buffer (in mM: NaCl 140, Hepes 10, D-glucose 5, KCl 4.7, EDTA 1, pH 7.3 with NaOH). After centrifugation (2 min, 14,000xg, 4 °C), the upper phase was collected and brought up to 20 ml with Krebs-Ringer-Hepes (KRH) solution (in mM: NaCl 113, NaHCO<sub>3</sub> 25, Hepes 20, D-glucose 15, KCl 4.7, CaCl<sub>2</sub> 1.8, MgCl<sub>2</sub> 1.2, KH<sub>2</sub>PO<sub>4</sub> 1.2, pH 7.4 with NaOH). The suspension was centrifuged (20,000xg, 20 min, 4 °C) and the pellet (synaptosomes) was re-suspended in KRH solution unless otherwise indicated.

## 2.7 Electron microscopy

Striatal synaptosomes were isolated by the Percoll method as above. Sample preparation and electron microscopy were performed as described in detail elsewhere (Morales-Figueroa *et al.*, 2015).

## 2.8 Radioligand binding assays with striatal membranes

Striatal synaptosomes were re-suspended in lysis solution (Tris-HCl 10 mM, EGTA 1 mM, pH 7.4) and incubated for 20 min at 4 °C before centrifugation (20 min, 20,000xg, 4 °C). The pellet (synaptosomal membranes) was re-suspended in 1 ml KRH solution containing adenosine deaminase (2 U/ml). After incubation for 30 min at 37 °C, the suspension was brought to 20 ml with KRH solution and centrifuged (20 min, 20,000xg, 4 °C). The membranes were re-suspended in incubation solution (Tris-HCl 50 mM, MgCl<sub>2</sub> 5 mM, pH 7.4) and 130 µl aliquots (40 µg protein) were incubated with 10 µl of increasing concentrations of CGS-21680 or RAMH (20x) and 50 µl of [<sup>3</sup>H]-NMHA (8 nM) or [<sup>3</sup>H]-CGS-21680 (48 nM). After 1 h at 30 °C ([<sup>3</sup>H]-NMHA) or 2 h at 25 °C ([<sup>3</sup>H]-CGS-21680), incubations were stopped by rapid filtration through Whatman GF/B filters pre-soaked (2 h) in 0.3 % polyethylenimine (PEI). Filters were washed 3 times with 1 ml ice-cold buffer solution (50 mM Tris-HCl, pH 7.4), soaked in 4 ml scintillation solution and the tritium content was determined by scintillation counting.

## 2.9 Co-immunoprecipitation assays

Striatal synaptosomes were obtained as described above and then re-suspended in 1 ml of lysis solution (Tris-HCl 50 mM, NaCl 150 mM, Triton X-100 1%, SDS 0.05%, protease inhibitor 1 µl/ml). HEK-293T cells were dislodged in RIPA solution. For both synaptosomal

and cell samples, protein was extracted by sonication (3 cycles, 30 sec, 8 kHz). The sample was centrifuged (20 min, 6,000xg) and the protein extract (supernatant) was collected. Nonspecific binding was removed by incubation (1 h, 4 °C) with 10 µl of AG beads (Santa Cruz Biotechnology; Dallas, TX, USA) under rotatory rocking. The beads were pelleted (2 min, 6000xg) and the supernatant was used for the assay. Protein quantification was performed by the BCA method.

The protein extracts (500 µg protein from striatal synaptosomes and 200 µg from HEK-293T) were incubated with 2 µg of the primary antibodies (anti-A<sub>2A</sub>R Abcam, cat. ab3461, lot. GR238882–9; anti-H<sub>3</sub>R, Abcam, cat. ab84468, lot. GR27494–1, in a 1:100 dilution) together with AG beads (Santa Cruz Biotechnology sc-2003, 1:5 antibody to beads ratio) for 16 h at 4°C with constant rotational rocking. Antibodies against the CD-81 protein (Santa Cruz Biotechnology, cat. sc-70803, lot. B0609) or D<sub>2</sub>R (Santa Cruz Biotechnology, cat. sc-5303, lot. A03013) were used as negative controls for the striatal synaptosomes or HEK-293T cells, respectively. The bead-antibody complex was pelleted (2 min, 6000xg) and a 30 µl aliquot of the supernatant was used as a load control. In both protein extracts, 30 µl of the total protein was used as input. The complex was dissociated for 60 min at 48°C in loading buffer (10% β-mercaptoethanol and 50% Laemmli buffer in H<sub>2</sub>O) and separated by electrophoresis in a 10% SDS-polyacrylamide gel (20 min at 80 V and then 65 min at 120 V). Semi-dry transfer was performed at 15 V for 95 min. Membranes were blocked with 5% nonfat dry milk diluted in TBS-Tween 0.05% solution (overnight, 4°C). After extensive washing, 5 ml of TBS-Tween 0.05% solution containing 5% BSA and the blotting antibody (anti-A<sub>2A</sub>R, anti-HA, Cell Signaling, cat. C29F4, lot. 3724S or anti-H<sub>3</sub>R, in a 1:1000 dilution) were added to the membrane and incubated overnight at 4 °C. Membranes were incubated with the secondary antibody (Invitrogen, HRP-conjugated anti-rabbit IgG, cat. 65–6120, 1:5000, non-fat dry milk 5% in TBS-Tween 0.05%) at room temperature for 2 h. For the loading controls membranes were incubated for 1 h with antibodies directed to β-tubulin (Invitrogen, cat. 322600, lot. 1235662) or α-actin (Sigma, cat. A5228, lot. 128K4843) in a 1:5000 dilution in TBST 0.05%. After washing, membranes were incubated for 1 h with the secondary antibody (α-mouse, Santa Cruz, cat. sc-2005) diluted in TBST 0.05%. Blot images were obtained by chemiluminescence in an X-ray film (Kodak).

## 2.10 Statistical analysis

Data show the mean ± standard error of the mean (SEM). Statistical analysis was performed with student *t*-test with Prisma GraphPad software, version 5.0 (San Diego, CA, USA).

## 3. Results

### 3.1 Co-immunoprecipitation of A<sub>2A</sub>Rs and H<sub>3</sub>Rs expressed in HEK-293 cells

We first studied by co-immunoprecipitation whether H<sub>3</sub>Rs and A<sub>2A</sub>Rs interact physically upon co-transfection in HEK-293T cells. 3xHA-H<sub>3</sub>Rs were detected after immunoprecipitation of wild type (WT) A<sub>2A</sub>Rs (Figure 1A). HEK-293T cells lack expression of the D<sub>2</sub> receptor, and an antibody targeting this receptor was therefore used as a negative control, yielding no signal. This result supports dimerization between H<sub>3</sub>Rs and A<sub>2A</sub>Rs.

### 3.2 Functional complementation of A<sub>2A</sub>Rs and H<sub>3</sub>Rs expressed in HEK-293 cells

To further study the potential interaction between A<sub>2A</sub>Rs and H<sub>3</sub>Rs in a recombinant cell system, we employed a functional complementation assay, previously used to study physical interactions between GPCRs (Han *et al.*, 2009; van Rijn *et al.*, 2013). This assay relies on the fusion of chimeric Gα<sub>qs4</sub> or Gα<sub>qi4</sub> proteins to the truncated C-terminal tail of a GPCR to generate a nonfunctional receptor, rescuable through homo- or hetero-dimerization with a WT, untruncated receptor. It was previously reported that fusion of a chimeric G protein to a GPCR truncated near helix 8 produces a receptor that is unable to signal by itself but can be rescued when transfected with a full-length receptor (van Rijn *et al.*, 2013). Therefore, we first generated an A<sub>2A</sub>R truncated to 302 residues (A<sub>2A</sub>R<sub>302</sub>) and H<sub>3</sub>Rs of 427, 421 and 411 residues (H<sub>3</sub>R<sub>427</sub>, H<sub>3</sub>R<sub>421</sub> and H<sub>3</sub>R<sub>411</sub>), and the truncated receptors were then fused to the chimeric G proteins (Figure 2A).

Activation of the H<sub>3</sub>R in transfected CHO-K1 cells and rat striatal neurons in primary culture induces Ca<sup>2+</sup> mobilization (Cogé *et al.*, 2001; Rivera-Ramirez *et al.*, 2016), and in the striatum A<sub>2A</sub>R activation favors Ca<sup>2+</sup> entry by modulating voltage-activated Ca<sup>2+</sup> channels (Kirk and Richardson, 1995; Gubitza *et al.*, 1996), which are endogenously expressed by HEK-293 cells (Berjukow *et al.*, 1996; Thomas and Smart, 2005). In HEK-293 cells, the H<sub>3</sub>R selective agonist RAMH did not induce any discernible Ca<sup>2+</sup> response but did so when the H<sub>3</sub>R was co-transfected with Gα<sub>qi4</sub> proteins (Figure 2B). The A<sub>2A</sub>R did not induce Ca<sup>2+</sup> signaling when activated by the selective agonist CGS-21680, but also no response was observed when co-transfected with Gα<sub>qs4</sub> proteins, suggesting that A<sub>2A</sub>Rs do not activate this chimeric protein (Figure 2C). It has been reported that not all GPCRs are amenable to signal through chimeric G-proteins (Conklin *et al.*, 1996). A different Gα<sub>s</sub>-coupled receptor, the histamine H<sub>2</sub> receptor, was capable to induce Ca<sup>2+</sup> release when co-transfected with Gα<sub>qs4</sub> proteins and stimulated with the selective agonist dimaprit (Supplementary Figure 1A), discarding Gα<sub>qs4</sub> malfunction. Consistent with the finding that A<sub>2A</sub>Rs did not signal efficiently via chimeric G-proteins, functional complementation by homodimerization of A<sub>2A</sub>R<sub>302</sub>-Gα<sub>qs4</sub> or A<sub>2A</sub>R<sub>302</sub>-Gα<sub>qi4</sub> with the full-length A<sub>2A</sub>R was not observed (Figure 2D).

The C-tail of the H<sub>3</sub>R was truncated such that the H<sub>3</sub>R-Gα<sub>qi4</sub> fusion protein would display limited Ca<sup>2+</sup> mobilization when expressed alone, but a pronounced Ca<sup>2+</sup> signaling when co-expressed with WT-H<sub>3</sub>Rs. The H<sub>3</sub>R<sub>421</sub>-Gα<sub>qi4</sub> and the H<sub>3</sub>R<sub>411</sub>-Gα<sub>qi4</sub> constructs did not induce Ca<sup>2+</sup> mobilization, and could not be rescued via homo-dimerization with WT-H<sub>3</sub>Rs (Supplementary Figure 1B). However, Ca<sup>2+</sup> mobilization induced by H<sub>3</sub>R<sub>427</sub>-Gα<sub>qi4</sub> upon activation and co-transfection with WT-H<sub>3</sub>Rs produced a similar increase in calcium release (Figure 2E). While not optimal, this behavior allowed for the study of the interaction between the H<sub>3</sub>R<sub>427</sub>-Gα<sub>qi4</sub> and the A<sub>2A</sub>R as described below.

Co-transfection of the 'inert' A<sub>2A</sub>R<sub>302</sub>-Gα<sub>qi4</sub> and H<sub>3</sub>Rs induced Ca<sup>2+</sup> mobilization after activation of the latter receptors with RAMH, suggestive of close physical proximity between the H<sub>3</sub>R and both the A<sub>2A</sub>R and the fused Gα<sub>qi4</sub>-protein. H<sub>3</sub>R activation failed to induce functional complementation in cells co-transfected with A<sub>2A</sub>R<sub>302</sub>-Gα<sub>qs4</sub> (Figure 3A). Given that H<sub>3</sub>Rs are Gα<sub>i/o</sub>-coupled, and the inability of the A<sub>2A</sub>R to signal through chimeric Gα<sub>qi4</sub>- or Gα<sub>qs4</sub>-proteins, it was not surprising that A<sub>2A</sub>R activation with the selective

agonist CGS-21680 did not produce any response through H<sub>3</sub>R<sub>427</sub>-Gα<sub>qs4</sub> or H<sub>3</sub>R<sub>427</sub>-Gα<sub>qi4</sub> (Figure 3B). Interestingly, the co-expression of WT-A<sub>2A</sub>Rs prevented RAMH-induced Ca<sup>2+</sup> mobilization mediated by the H<sub>3</sub>R<sub>427</sub>-Gα<sub>qi4</sub> (compare Figure 2E and Figure 3C). We briefly explored this pharmacological response further by analyzing Ca<sup>2+</sup> mobilization in HEK-293T cells co-expressing the H<sub>3</sub>R<sub>427</sub>-Gα<sub>qi4</sub> and the A<sub>2A</sub>R or the A<sub>2A</sub>R<sub>302</sub>-Gα<sub>qi4</sub> and the H<sub>3</sub>R and activating both receptors, but did not observe any additive or antagonistic effect (Supplementary Figure 1C and 1D).

A<sub>2A</sub>Rs have been shown to form heteromers with D<sub>2</sub>Rs (Ferré *et al.*, 2003) and robust functional complementation was accordingly observed when A<sub>2A</sub>R-Gα<sub>qi4</sub> was co-expressed with WT-D<sub>2</sub>Rs (Figure 3D), supporting that our results are due to heterodimerization and not to stochastic interactions.

### 3.3 The putative A<sub>2A</sub>R-H<sub>3</sub>R heteromer displays ligand bias

To test for the selective nature of the A<sub>2A</sub>R-H<sub>3</sub>R interaction in the functional complementation assay, we investigated if A<sub>2A</sub>R-Gα<sub>qi4</sub> would also allow the structurally and physiologically similar histamine H<sub>4</sub> receptor (H<sub>4</sub>R) to induce Ca<sup>2+</sup> signaling. Co-activation with histamine of H<sub>3</sub>Rs and H<sub>4</sub>Rs elicited Ca<sup>2+</sup> mobilization only when co-transfected with Gα<sub>qi4</sub> (Supplementary Figure 2A and 2B, respectively). Neither histamine nor RAMH induced Ca<sup>2+</sup> mobilization when the H<sub>4</sub>R was co-expressed with A<sub>2A</sub>R<sub>302</sub>-Gα<sub>qi4</sub>, supporting the specificity of the A<sub>2A</sub>R-H<sub>3</sub>R interaction (Figure 3E). Unexpectedly, whereas RAMH induced Ca<sup>2+</sup> mobilization when the H<sub>3</sub>R was co-expressed with A<sub>2A</sub>R<sub>302</sub>-Gα<sub>qi4</sub>, histamine did not (compare Figure 3A with Figure 3F). This result suggests that the A<sub>2A</sub>R-H<sub>3</sub>R heteromer displays agonist bias.

### 3.4 A<sub>2A</sub>R-mediated signaling is increased by H<sub>3</sub>R co-activation

To study the pharmacology of the putative A<sub>2A</sub>R-H<sub>3</sub>R heteromer we next tested cAMP signaling using WT receptors in HEK-293T cells. In cells transfected with the A<sub>2A</sub>R, incubation with CGS-21680 resulted in a concentration-dependent increase in cAMP levels in accordance with the receptor's coupling to the Gα<sub>s</sub> signaling pathway (Figure 3A). CGS-21680 induced a similar cAMP response in HEK293T-A<sub>2A</sub>R cells co-expressing H<sub>3</sub>Rs (Figure 4A). Co-activation of the receptors resulted in a decrease in baseline, in agreement with the Gα<sub>i/o</sub> coupling of the H<sub>3</sub>R, but led to an augmentation of A<sub>2A</sub>R-mediated cAMP formation as noticed by a 2.5-fold change of baseline (versus 1.5-fold in control). This result suggests that the A<sub>2A</sub>R signaling becomes more efficacious when heterodimerization with the H<sub>3</sub>R occurs (Figure 4A, Supplementary Figure 2C, and Table 2). The increase in the A<sub>2A</sub>R signaling was not observed in the absence of RAMH (1.5-fold of baseline) suggesting an agonist-dependency of the response (Figure 4A and Supplementary Figure 2C).

In HEK293T-H<sub>3</sub>R cells, RAMH inhibited forskolin-stimulated cAMP formation congruent with the Gα<sub>i/o</sub> coupling of the H<sub>3</sub>R receptor. However, when the A<sub>2A</sub>R was co-transfected, RAMH-mediated H<sub>3</sub>R signaling shifted to facilitate cAMP formation instead. Activation of the A<sub>2A</sub>R caused an expected increase in the baseline but did not significantly modify the effect on cAMP formation. This result suggests that in the heterodimer, A<sub>2A</sub>R signaling prevails over the H<sub>3</sub>R signaling (Figure 4B and Supplementary Figure 2D; Table 2).



### 3.5 H<sub>3</sub>R activation decreases A<sub>2A</sub>R binding affinity in synaptosomal membranes

The identification of A<sub>2A</sub>R-H<sub>3</sub>R heteromers was performed in recombinant cell systems over-expressing the receptors. As previously mentioned A<sub>2A</sub>Rs and H<sub>3</sub>Rs are co-expressed in iMSNs and cortico-striatal projections. We therefore used rat striatal synaptosomes to seek for pharmacological traces that supported the existence of native A<sub>2A</sub>R-H<sub>3</sub>R dimers.

Electron microscopy confirmed in the purified synaptosomal preparation the vast presence and conserved structure of isolated nerve terminals, characterized by a delimited membrane and the presence of mitochondria and synaptic vesicles (Supplementary Figure 3A and B). In protein extracts from striatal synaptosomes, immunoprecipitation of the A<sub>2A</sub>R resulted in a band of ~45 kDa, corresponding to the expected migration of the H<sub>3</sub>R. No signal was detected when an irrelevant antibody ( $\alpha$ -CD81) was tested. As a positive control the H<sub>3</sub>R was immunoprecipitated and detected as a band of ~45 kDa (Figure 5A). When the reverse approach was employed and the H<sub>3</sub>R was immunoprecipitated from the striatal protein extracts, a band of ~45 kDa corresponding to the expected migration of the A<sub>2A</sub>R was observed. This band was also observed when the A<sub>2A</sub>R was immunoprecipitated as a positive control but not detected in the negative control (Figure 5B). This result supports that the interaction A<sub>2A</sub>R-H<sub>3</sub>R is constitutively present in the striatal nerve terminals.

In binding studies with synaptosomal membranes the A<sub>2A</sub>R agonist CGS-21680 (10 and 100 nM) did not affect the affinity of the H<sub>3</sub>R for its agonist RAMH (Figure 6A), whereas RAMH (100 nM) decreased by two-fold the affinity of the A<sub>2A</sub>R for CGS-21680 (Figure 6B, 6C and Table 3), with no effect on maximal binding (B<sub>max</sub>). This pharmacology appears to be specific for pre-synaptic H<sub>3</sub>Rs and A<sub>2A</sub>Rs, because we did not observe a similar decrease in A<sub>2A</sub>R affinity for CGS-21680 in membranes from the whole striatum, in which post-synaptic membranes constitute the major component (Figure 6D and Table 3).

## 4. Discussion

The H<sub>3</sub>R has been proposed as a potential novel drug target for the treatment of drug use disorders, depression, schizophrenia, and Parkinson's disease. However, its wide brain expression and effects on other neurotransmitter systems may result in adverse effects when H<sub>3</sub>R selective drugs are administered systemically. The A<sub>2A</sub>R has also been proposed as an option for the treatment of Parkinson's disease and possesses a strategic distribution in the striatum for targeting and modulating the cortico-dMSNs projections and the activity of iMSNs. The results presented herein may lead to an alternative to specifically target H<sub>3</sub>Rs located in either iMSNs or cortical afferents synapsing onto dMSNs projections.

### 4.1 A<sub>2A</sub>R-H<sub>3</sub>R interaction

The primary finding of this study was the identification, for the first time, of A<sub>2A</sub>R-H<sub>3</sub>R heteromers, not only in recombinant cell systems but also in rat striatal nerve terminals.

The basis of the functional complementation assays requires a receptor to be nonfunctional and this was obtained by truncation of the C-terminus. Herein we showed that truncation of the H<sub>3</sub>R from 445 to 411 or 421 residues was sufficient to prevent H<sub>3</sub>R-mediated G protein activation of the H<sub>3</sub>R-G $\alpha_{q14}$  fusion protein, yet we were unable to functionally rescue its

signaling, indicating that the remaining C-tail may be too short to connect with an interacting GPCR. However, truncation to 427 amino acids allowed the H<sub>3</sub>R to remain functional.

Exposure of HEK-293T cells transfected with H<sub>3</sub>R<sub>427</sub>-Gα<sub>q14</sub> to the H<sub>3</sub>R agonist RAMH resulted in Ca<sup>2+</sup> mobilization (Figure 1E). As mentioned in the Results section, this response was not expected. In an optimal scenario, the receptor truncation would have prevented or diminished the receptor capability to activate G proteins and the H<sub>3</sub>R<sub>427</sub>-Gα<sub>q14</sub> function was expected to be either complemented or increased by the co-expression and co-activation with the WT-H<sub>3</sub>R. However, these conditions allowed for the detection of the loss of H<sub>3</sub>R function with the solely presence of the A<sub>2A</sub>R, suggesting a preference of the H<sub>3</sub>R to form hetero-dimers over homo-dimers. It may be possible that truncating the H<sub>3</sub>R at the amino acids 421–427 will result in a receptor short enough to abolish the homo/monomeric signaling, but long enough to functionally complement with a full length GPCR.

In order for a GPCR to activate G proteins, the integrity of helix 8 appears to be required. This structural requirement has been demonstrated for D<sub>1</sub>Rs and opioid κ and μ receptors (van Rijn *et al.*, 2013). The H<sub>3</sub>R third intracellular loop also appears to play a key role in the receptor-G protein coupling on the basis of the decreased signaling of the H<sub>3</sub>R<sub>365</sub> isoform, which lacks 80 residues in the third intracellular loop (Riddy *et al.*, 2016), and reduced signaling was induced by the A280V mutation in the same loop (Flores-Clemente *et al.*, 2013). Further consideration to the H<sub>3</sub>R carboxyl tail should therefore be made when assessing the H<sub>3</sub>R-G protein coupling.

An important issue when describing a novel heterodimer is to show changes in the signaling profiles of the receptors involved in the dimer. In this regard, we found enhanced signaling efficacy of the agonist CGS-21680 when the H<sub>3</sub>R was co-transfected and co-activated in the HEK293T-A<sub>2A</sub>R cells. This effect can be explained by a H<sub>3</sub>R-mediated facilitation of the A<sub>2A</sub>R-G protein coupling, leading to an increase in the receptor efficacy to activate Gα<sub>s</sub> proteins and thus to produce cAMP. Given that in the absence of RAMH, CGS-21680 behaved the same in HEK293T-A<sub>2A</sub>R and HEK293T-A<sub>2A</sub>R/H<sub>3</sub>R cells, receptor expression does not appear to account for the observed effects.

Canonically H<sub>3</sub>Rs couple to Gα<sub>i/o</sub> proteins, which inhibit adenylyl cyclase activity and accordingly activation of the receptor with RAMH lead to a decrease in cAMP formation. Similar to the observed in the Ca<sup>2+</sup> mobilization assays, expression of the A<sub>2A</sub>R shifted the H<sub>3</sub>R-mediated cAMP response from inhibition to an increase in the cAMP formation. In the Ca<sup>2+</sup> mobilization assays we did not observe signaling of the H<sub>3</sub>R through Gα<sub>q14</sub> proteins bound to the truncated A<sub>2A</sub>R, and we are thus not considering a H<sub>3</sub>R change in signaling pathways as an explanation for this effect. Therefore, we hypothesized that in the A<sub>2A</sub>R-H<sub>3</sub>R heteromer the A<sub>2A</sub>R signaling prevails over that of the H<sub>3</sub>R, hampered possibly by a steric impediment. This is in line with the loss of Ca<sup>2+</sup> signaling when the H<sub>3</sub>R-Gα<sub>q14</sub> was co-expressed with the A<sub>2A</sub>R.

An unexpected but interesting finding was the potential biased-signaling at the A<sub>2A</sub>R-H<sub>3</sub>R heteromer, as evidenced by the incapability of the endogenous ligand histamine to signal at

the A<sub>2A</sub>R-H<sub>3</sub>R heteromer compared to the exogenous agonist RAMH. This discrepancy suggests that RAMH induces conformational changes in the H<sub>3</sub>R that allow the interaction to occur, whereas histamine-induced changes appear not sufficient for heteromerization, or at least for the heteromer to signal. Ligand bias could also be explained by agonist residence time, this is, the time that a particular drug remains in its binding pocket and that will directly determine the time that a given receptor maintains an active conformation. The active state induced by histamine may therefore have a shorter duration compared with that induced by RAMH, preventing the former from activating the chimeric G proteins bound to the A<sub>2A</sub>R<sub>302</sub>. Binding studies with striatal membranes and histamine show that the first hypothesis holds better because histamine induced an increase in the affinity of the A<sub>2A</sub>R for its agonist CGS-21680 (Supplementary Figure 4), opposite to the decrease in affinity change induced by RAMH in the same preparation. This result suggests that histamine and RAMH lock the H<sub>3</sub>R in different conformational states that affect its interaction with the A<sub>2A</sub>R.

#### 4.2 Functional relevance of the A<sub>2A</sub>R-H<sub>3</sub>R heterodimer

Our results suggest a pre-synaptic location of the A<sub>2A</sub>R-H<sub>3</sub>R heterodimer in the striatum. A previous report indicates equal distribution of A<sub>2A</sub>R<sub>s</sub> in total and synaptosomal membranes from rat striatum (Rebola *et al.*, 2005), with a preferential location on the post-synaptic density fraction over the pre-synaptic active zone fraction ( $49.2 \pm 3.3$  % and  $26.9 \pm 3.3$  % of total immunoreactivity, respectively). H<sub>3</sub>R<sub>s</sub> are expressed pre- and post-synaptically (Ellenbroek and Ghiabi, 2014), but they seem to be highly enriched in the terminals of striato-pallidal neurons (iMSNs) yielding a value of  $1,327 \pm 79$  fmol/mg protein (Morales-Figueroa *et al.*, 2014). This distribution supports our proposal for the heterodimer location and suggests a role for the A<sub>2A</sub>R-H<sub>3</sub>R heteromer in the pre-synaptic modulation of glutamatergic and GABAergic transmission.

In the striatum, A<sub>2A</sub>R<sub>s</sub> have a specific location in iMSNs (Schiffman *et al.*, 1991) and cortico-dMSNs terminals, but not in the cortico-iMSNs projections (Quiróz *et al.*, 2009) whereas the H<sub>3</sub>R is ubiquitously expressed throughout the striatum (Nieto-Alamilla *et al.*, 2016). Both receptors can modulate the cortico-striatal glutamatergic and intra-striatal GABAergic transmission, but whereas the H<sub>3</sub>R consistently inhibits neurotransmitter release in either location, the A<sub>2A</sub>R facilitates cortico-striatal glutamate release but inhibits GABA release from the iMSNs collaterals.

Our data depicts thus a scenario where the A<sub>2A</sub>R and the H<sub>3</sub>R preserve their canonical signaling pathways (Gα<sub>s</sub> and Gα<sub>i/o</sub>, respectively), and upon dimerization the H<sub>3</sub>R facilitates the A<sub>2A</sub>R signaling. This receptor functionality is preserved in the cortico-dMSNs projections, with A<sub>2A</sub>R activation enhancing glutamate release (Popoli *et al.*, 1995) and H<sub>3</sub>R<sub>s</sub> exerting the opposite effect (Arias-Montañó *et al.*, 2001). Activation of the A<sub>2A</sub>R-H<sub>3</sub>R heterodimer in these terminals may further facilitate glutamate release, resulting in hyperstimulation of the dMSNs population.

Contrary to the A<sub>2A</sub>R and H<sub>3</sub>R antagonistic modulation of glutamatergic transmission, both receptors inhibit GABA release from iMSNs collaterals. This may be due to the A<sub>2A</sub>R functional duality showed in this neuronal population, as demonstrated by its capability to activate Gα<sub>s</sub> and Gα<sub>q</sub> proteins (Gubitza *et al.*, 1995; Kirk and Richardson, 1996). Therefore,

we hypothesized that the activation of the A<sub>2A</sub>R-H<sub>3</sub>R heterodimer in this location will further inhibit GABA release from iMSN nerve terminals, facilitating the activation of the dMSNs. According to this hypothesis, the overall activation of the striatal A<sub>2A</sub>R-H<sub>3</sub>R heterodimer would increase dMSNs activity. It is therefore tempting to speculate that co-activation of the heterodimer may have relevance for the treatment of the autism and obsessive and compulsive disorder, in which alterations in cortico-striatal glutamatergic transmission and MSN excitability have been shown (Welch *et al.*, 2008; Naaijen *et al.*, 2017).

Furthermore, it has been reported that the A<sub>2A</sub>R antagonists KW-6002 and SCH-442416 can distinguish receptors located in the cortical afferents targeting dMSNs or iMSNs, respectively (Orrú *et al.*, 2011). Although there are no agonists capable to differentiate between A<sub>2A</sub>R populations, this information may be a valuable tool for targeting and modulating the A<sub>2A</sub>R and H<sub>3</sub>R pharmacology in a location-specific manner, using bivalent ligands directed to the heterodimer.

## 5. Conclusion

This study presents for the first time evidence for an A<sub>2A</sub>R-H<sub>3</sub>R heterodimer based on functional complementation and co-immunoprecipitation assays in HEK-293 cells, where co-activation of the receptors leads to enhanced A<sub>2A</sub>R signaling and attenuation of H<sub>3</sub>R functionality. In rat striatal tissue, the interaction occurs in synapses where H<sub>3</sub>R activation modifies the binding affinity of the A<sub>2A</sub>R.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

We thank Juan Escamilla-Sánchez and Raúl González-Pantoja for excellent technical assistance. We also thank Sirenia González for help in obtaining the synaptosomal MET images. R. M.-G. held a Conacyt graduate scholarship (244993).

### Funding

This work was supported by Cinvestav, Conacyt (grant 220448 to J.-A. A.-M.), PAPIIT-UNAM (grant IN216215 to J.-M. A.), the National Institute on Alcohol Abuse and Alcoholism (grant AA20539 to R. M. v R.) and the Ralph W. and Grace M. Showalter Research Trust (to R. M. v R.). The funding sources were not involved at all in the study design, collection, analysis and interpretation of data, writing of the manuscript or the decision to submit this report.

## Abbreviations

<b>A<sub>2A</sub>R</b>	Adenosine A <sub>2A</sub> receptor
<b>cAMP</b>	Cyclic adenosine monophosphate
<b>D<sub>1</sub>R</b>	Dopamine D <sub>1</sub> receptor
<b>D<sub>2</sub>R</b>	Dopamine D <sub>2</sub> receptor


<b>dMSNs</b>	Direct pathway striatal medium-sized spiny neurons
<b>GABA</b>	$\gamma$ -Aminobutyric acid
<b>GPCRs</b>	G-protein coupled receptors
<b>H<sub>2</sub>R</b>	Histamine H <sub>2</sub> receptor
<b>H<sub>3</sub>R</b>	Histamine H <sub>3</sub> receptor
<b>H<sub>4</sub>R</b>	Histamine H <sub>4</sub> receptor
<b>iMSNs</b>	Indirect pathway striatal medium-sized spiny neurons
<b>MSNs</b>	Striatal medium-sized spiny neurons
<b>RAMH</b>	(R)- $\alpha$ -methylhistamine
<b>WT</b>	Wild type

## 6. References

- Arias-Montaña JA, Floran B, Garcia M, Aceves J, Young JM, 2001 Histamine H<sub>3</sub> receptor-mediated inhibition of depolarization-induced, dopamine D<sub>1</sub> receptor-dependent release of [<sup>3</sup>H]-gamma-aminobutyric acid from rat striatal slices. *Br J Pharmacol* 133:165–171 [PubMed: 11325806]
- Berjukow S, Döring F, Froschmayr M, Grabner M, Glossmann H, Hering S, 1996 Endogenous calcium channels in human embryonic kidney (HEK293) cells. *Br J Pharmacol* 118:748–754 [PubMed: 8762103]
- Bolam JP, Hanley JJ, Booth PA, Bevan MD, 2000 Synaptic organization of the basal ganglia. *J Anat* 196:527–542 [PubMed: 10923985]
- Bolam PJ, Ellender TJ, 2016 Histamine and the striatum. *Neuropharmacology* 106:74–84 [PubMed: 26275849]
- Cabello N, Gandía J, Bertarelli DCG, Watanabe M, Lluís C, Franco R, Ferré S, Luján R, Ciruela F, 2009 Metabotropic glutamate type 5, dopamine D<sub>2</sub> and adenosine A<sub>2a</sub> receptors from higher-order oligomers in living cells. *J Neurochem* 109:1497–1507 [PubMed: 19344374]
- Carriba P, Ortiz O, Patkar K, Justinova Z, Stroik J, Themann A, Muller C, Woods AS, Hope BT, Ciruela F, Casadó V, Canela EI, Lluís C, Goldberg SR, Moratalla R, Franco R, Ferré S, 2007 Striatal adenosine A<sub>2A</sub> and cannabinoid CB<sub>1</sub> receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. *Neuropsychopharmacology* 32:2249–2259
- Chiang T, Sansuk K, van Rijn RM, 2016  $\beta$ -arrestin 2 dependence of  $\delta$  opioid receptor agonists is correlated with alcohol intake. *Br J Pharmacol* 173:332–343 [PubMed: 26507558]
- Ciruela F, Casadó V, Rodrigues RJ, Luján R, Burgueño J, Canals M, Borycz J, Rebola N, Goldberg SR, Mallol J, Cortés A, Canela EI, López-Giménez JF, Milligan G, Lluís C, Cunha RA, Ferré S, Franco R, 2006 Presynaptic control of striatal glutamatergic neurotransmission by adenosine A<sub>1</sub>-A<sub>2A</sub> receptor heteromers. *J Neurosci* 26:2080–2087 [PubMed: 16481441]
- Cogé F, Guénin SP, Audinot V, Renouard-Try A, Beauverger P, Macia C, Ouvre C, Nagel N, Rique H, Boutin JA, Galizzi JP, 2001 Genomic organization and characterization of splice variants of the human histamine H<sub>3</sub> receptor. *Biochem J* 355:279–288 [PubMed: 11284713]
- Conklin BR, Herzmark P, Ishida S, Voyno-Yasenetskaya TA, Sun Y, Farfel Z, Bourne HR, 1996 Carboxyl terminal mutations of Gq alpha and Gs alpha that alter the fidelity of receptor activation. *Mol Pharmacol* 50:885–890 [PubMed: 8863834]
- Doreulee N, Yanovsky Y, Flagmeyer I, Stevens DR, Haas HL, Brown RE, 2001 Histamine H<sub>3</sub> receptors depress synaptic transmission in the corticostriatal pathway. *Neuropharmacology* 40:106–113 [PubMed: 11077076]


12. Ellenbroek BA, 2013 Histamine H<sub>3</sub> receptors, the complex interaction with dopamine and its implications for addiction. *Br J Pharmacol* 170:46–57 [PubMed: 23647606]
13. Ellenbroek BA, Ghiabi B, 2014 The other side of the histamine H<sub>3</sub> receptor. *Trends Neurosci* 37:191–199 [PubMed: 24636456]
14. Ferré S, Ciruela F, Canals M, Marcellino D, Burqueno J, Casadó V, Hillion J, Torvinen M, Fanelli F, Benedetti PD, Goldberg SR, Bouvier M, Fuxe K, Agnati LF, Lluís C, Franco R, Woods A, 2004 Adenosine A<sub>2A</sub>-dopamine D<sub>2</sub> receptor-receptor heteromers. *Targets for neuro-psychiatric disorders Parkinsonism. Relat Disord* 10:265–271
15. Ferré S, Fredholm BB, Moreli M, Popoli P, Fuxe K, 1997 Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. *Trends Neurosci* 20:482–487 [PubMed: 9347617]
16. Flores-Clemente C, Osorio-Espinoza A, Escamilla-Sánchez J, Leurs R, Arias JM, Arias-Montaña JA, 2013 A single-point mutation (Ala280Val) in the third intracellular loop alters the signaling properties of the human histamine H<sub>3</sub> receptor stably expressed in CHO-K1 cells. *Br J Pharmacol* 170:127–135 [PubMed: 23713487]
17. Gonzalez-Sepulveda M, Rosell S, Hoffman HM, del Mar. Castillo-Ruiz Ma., Mignon V, Moreno-Delgado D, Vignes M, Diaz J, Sabria J, Ortiz J, 2013 Cellular distribution of the histamine H<sub>3</sub> receptor in the basal ganglia: Functional modulation of dopamine and glutamate neurotransmission. *Basal Ganglia* 3:109–121
18. Gubitz AK, Widdowson L, Kurokawa M, Kirkpatrick KA, Richardson PJ, 1996 Dual signaling by the adenosine A<sub>2a</sub> receptor involves activation of both N- and P-type calcium channels by different G proteins and protein kinases in the same striatal nerve terminals. *J Neurochem* 67:374–381 [PubMed: 8667016]
19. Han Y, Moreira IS, Urizar E, Weinstein H, Javitch JA, 2009 Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. *Nat Chem Biol* 5:688–695 [PubMed: 19648932]
20. Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, Hansson A, Watson S, Olah ME, Canela EI, Zoli M, Agnati LF, Ibanez CF, Lluís C, Franco R, Ferré S, Fuxe K, 2002 Coaggregation, cointernalization, and codesensitization of adenosine A<sub>2A</sub> receptors and dopamine D<sub>2</sub> receptors. *J Biol Chem* 277:18091–18097 [PubMed: 11872740]
21. Kemp JM, Powell TP, 1971 The structure of caudate nucleus of the cat: light and electron microscopy. *Philos Trans R Soc Lond B Biol Sci* 262:383–401.
22. Kirk IP and Richardson PJ, 1994 Adenosine A<sub>2a</sub> receptor-mediated modulation of striatal [<sup>3</sup>H]GABA and [<sup>3</sup>H]acetylcholine release. *J Neurochem* 62:960–966 [PubMed: 8113816]
23. Kirk IP, Richardson PJ, 1995 Inhibition of striatal GABA release by the adenosine A<sub>2A</sub> receptor is not mediated by increase in cyclic AMP. *J Neurochem* 64:2801–2808 [PubMed: 7760061]
24. Márquez-Gómez R, Gutierrez-Rodelo C, Robins MT, Escamilla-Sánchez J, Olivares-Reyes J-A, van Rijn R, Arias-Montaña J-A, 2016 On the existence of a histamine H<sub>3</sub>-adenosine A<sub>2A</sub> receptor heteromer. *Inflamm Res* 65 (Suppl. 1), S29
25. Marquez-Gomez R, Gutierrez-Rodelo C, Robins MT, Arias J-M, Olivares-Reyes J-A, van Rijn RM, Arias-Montaña J-A, 2017 Functional histamine H<sub>3</sub> and adenosine A<sub>2A</sub> receptor heteromers in recombinant cells and rat striatum. *bioRxiv* 171736; doi: 10.1101/171736
26. Morales-Figueroa GE, Márquez-Gómez R, González-Pantoja R, Escamilla-Sanchez J, Arias-Montaña JA, 2015 Histamine H<sub>3</sub> receptor activation counteracts adenosine A<sub>2A</sub> receptor-mediated enhancement of depolarization-evoked [<sup>3</sup>H]-GABA release from rat globus pallidus synaptosomes. *ACS Chem Neurosci* 20:637–645
27. Moreno E, Moreno-Delgado D, Navarro G, Hoffmann HM, Fuentes S, Rosell-Vilar S, Gasperini P, Rodriguez-Ruiz M, Medrano M, Mallol J, Cortés A, Casadó V, Lluís C, Ferré S, Ortiz J, Canela E, McCormick PJ, 2014 Cocaine disrupts histamine H<sub>3</sub> receptor modulation of dopamine D<sub>1</sub> receptor signaling:  $\sigma_1$ -D<sub>1</sub>-H<sub>3</sub> receptor complexes as key targets for reducing cocaine's effects. *J Neurosci* 34:3545–3558 [PubMed: 24599455]
28. Naaijen J, Zwier MP, Amiri H, Williams SCR, Durston S, Oranje B, Brandeis D, Boecker-Schlier R, Ruf M, Wolf I, Banaschewski T, Glennon JC, Franke B, Buitelaar JK, Lythgoe DJ, 2017

- Fronto-striatal glutamate in autism spectrum disorders and obsessive compulsive disorder. *Neuropsychopharmacology* 42:2456–2465 [PubMed: 27869141]
29. Nieto-Alamilla G, Márquez-Gómez R, García-Gálvez A-M, Morales-Figueroa G-E, Arias-Montaño J-A, 2016 The histamine H<sub>3</sub> receptor: structure, pharmacology and function. *Mol Pharmacol* 90:649–673 [PubMed: 27563055]
30. Panula P, Nuutinen S, 2013 The histaminergic network in the brain: basic organization and role in disease. *Nat Rev Neurosci* 14:472–487 [PubMed: 23783198]
31. Panula P, Chazot PL, Cowart M, Gutzmer R, Leurs R, Liu WLS, Stark H, Thurmond RL, Haas HL, Ohlstein EH, 2015 International union of basic and clinical pharmacology. XCVIII. Histamine receptors. *Pharmacol Rev* 67:601–655 [PubMed: 26084539]
32. Passani MB, Blandina P, 2011 Histamine receptors in the CNS as target for therapeutic intervention. *Trends Pharmacol Sci* 32:242–249 [PubMed: 21324537]
33. Pillot C, Heron A, Cochois V, Tardivel-Lacombe J, Ligneau X, Schwartz J-C, Arrang J-M, 2002 A detailed mapping of the histamine H<sub>3</sub> receptor and its gene transcripts in rat brain. *Neuroscience* 114:173–193 [PubMed: 12207964]
34. Popoli P, Betto P, Reggio R, Ricciarello G, 1995 Adenosine A<sub>2A</sub> receptor stimulation enhances striatal extracellular glutamate levels in rats. *Eur J Pharmacol* 287:215–217 [PubMed: 8749040]
35. Prast H, Tran MH, Fischer H, Kraus M, Lamberti C, Grass K, Philippu A, 1999 Histaminergic neurons modulate acetylcholine release in the ventral striatum: role of H<sub>3</sub> histamine receptors. *Naunyn Schmiedebergs Arch Pharmacol* 360:558–564 [PubMed: 10598795]
36. Quiroz C, Luján R, Chigashima M, Simoes AP, Lerner TN, Borycz J, Kachroo A, Canas PM, Orru M, Schwarzschild MA, Rosin DL, Kreitzer AC, Cunha RA, Watanabe M, Ferré S, 2009 Key modulatory role of presynaptic adenosine A<sub>2A</sub> receptors in cortical neurotransmission to the striatal direct pathway. *Scientific World Journal* 18:1321–1344
37. Riddy DM, Cook AE, Diepenhorst NA, Bosnyak S, Brady R, Mannoury la Cour C, Mocaer E, Summers RJ, Charman WN, Sexton PM, Christopoulos A, Langmead CJ, 2016 Isoform-specific biased agonism of histamine H<sub>3</sub> receptor agonists. *Mol Pharmacol* 91:87–99 [PubMed: 27864425]
38. Rivera-Ramírez N, Montejo-López W, López-Méndez MC, Guerrero-Hernández A, Molina-Hernández A, García-Hernández U, Arias-Montaño JA, 2016 Histamine H<sub>3</sub> receptor activation stimulates calcium mobilization in a subpopulation of rat striatal neurons in primary culture, but not in synaptosomes. *Neurochem Int* 101:38–47 [PubMed: 27744004]
39. Rodríguez-Ruiz M, Moreno E, Moreno-Delgado D, Navarro G, Mallol J, Cortés A, Lluís C, Canela EI, Casadó V, McCormick PJ, Franco R, 2017 Heteroreceptor complexes formed by dopamine D<sub>1</sub>, histamine H<sub>3</sub>, and N-Methyl-D-Aspartate glutamate receptors as targets to prevent neuronal death in Alzheimer's disease. *Mol Neurobiol* 54:4537–4550 [PubMed: 27370794]
40. Schiffmann SN, Jacobs O, Vanderhaeghen JJ, 1991 Striatal restricted adenosine A<sub>2</sub> receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. *J Neurochem* 57:1062–1067 [PubMed: 1713612]
41. Schliker E, Fink K, Detzner M, Gothert M, 1993 Histamine inhibits dopamine release in the mouse striatum via presynaptic H<sub>3</sub> receptors. *J Neural Transm Gen Sect* 93:1–10 [PubMed: 8396945]
42. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M, 2006 Targeting adenosine A<sub>2A</sub> receptor in Parkinson's disease. *Trends Neurosci* 29:647–654 [PubMed: 17030429]
43. Tapper JM, Kóos T, Wilson CJ, 2004 GABAergic microcircuits in the neostriatum. *Trends Neurosci* 27:662–669. [PubMed: 15474166]
44. Thomas P, Smart TG, 2005 HEK293 cells line: A vehicle for the expression of recombinant proteins. *J Pharmacol and Toxicol Methods* 51:187–200 [PubMed: 15862464]
45. van Rijn RM, Harvey JH, Brissett DI, DeFriel JN, Whistler JL, 2013 Novel screening assay for the selective detection of G-protein-coupled receptor heteromer signaling. *J Pharmacol Exp Ther* 344:179–188 [PubMed: 23097213]
46. Welch JM, Lu J, Rodriguez RM, Trotta NC, Peca J, Ding J-D, Feliciano C, Chen M, Adams JP, Luo J, Dudek SM, Weinberg RJ, Calakos N, Wetsel WC, Feng G, 2008 Cortico-striatal synaptic defects and OCD-like behaviors in SPAP3 mutant mice. *Nature* 448:894–900




**Figure 1.** Adenosine A<sub>2A</sub> and histamine H<sub>3</sub> receptors co-immunoprecipitate in transfected HEK-293 cells. A. Co-immunoprecipitation of the hemagglutinin-tagged H<sub>3</sub>R (3xHA-H<sub>3</sub>R) with the A<sub>2A</sub>R in protein extracts from HEK-293 cells. The ~45 kDa band corresponds to the 3xHA-H<sub>3</sub>R, and was not observed with the negative control. Input represents 30% of the total protein. An antibody against the D<sub>2</sub> receptor ( $\alpha$ -D<sub>2</sub>R) was used as a negative control. The blot is representative of 3 independent experiments. The whole blot is shown in Supplementary Figure 5.






**Figure 2.**

Study of the possible A<sub>2A</sub>R-H<sub>3</sub>R dimerization by functional complementation assay. A. Basis of the assay. The G protein-coupled receptor (GPCR; grey cylinders) is truncated at its carboxyl terminus to generate a nonfunctional GPCR, which is then fused to the chimeric G protein (green hexagons). The chimeric G protein is formed by a Gα<sub>q</sub> protein in which 9 or 10 residues of the C-terminus were substituted by the corresponding sequence of a Gα<sub>s4</sub> or Gα<sub>i4</sub> protein (represented by X). Under these conditions, Ca<sup>2+</sup> mobilization can only be elicited when the complex GPCR-Gα<sub>qx</sub> is in close proximity to a wild type (WT) GPCR, either the same (homodimerization) or a different receptor (heterodimerization). B. Activation of the H<sub>3</sub>R with its agonist RAMH resulted in Ca<sup>2+</sup> mobilization only when it was co-expressed with the chimeric Gα<sub>qi4</sub> but not when transfected alone. C. When activated with its agonist CGS-21680, the A<sub>2A</sub>R was incapable to induce Ca<sup>2+</sup> mobilization either alone or when co-transfected with the chimeric Gα<sub>qs4</sub> protein. D. Functional complementation by homodimerization of the truncated A<sub>2A</sub>R<sub>302</sub>, either bound to Gα<sub>qs4</sub> (A<sub>2A</sub>R<sub>302</sub>-Gα<sub>qs4</sub>) or Gα<sub>qi4</sub> (A<sub>2A</sub>R<sub>302</sub>-Gα<sub>qi4</sub>), with the native A<sub>2A</sub>R was not observed. E. Activation of the truncated H<sub>3</sub>R<sub>427</sub> bound to Gα<sub>qi4</sub> (H<sub>3</sub>R<sub>427</sub>-Gα<sub>qi4</sub>) induced Ca<sup>2+</sup> mobilization on its own and homodimerization with the WT-H<sub>3</sub>R did not modify the response. No signal was observed with activation of the H<sub>3</sub>R<sub>427</sub>-Gα<sub>qs4</sub> construct when it was co-expressed with the WT-H<sub>3</sub>R. In all graphs data are means ± SEM from 3 replicates from a representative experiment. Where SEM bars are not visible, they are smaller than the symbol size. The quantitative analysis is shown in Tables 1 and Supplementary Table 2.




**Figure 3.**

Ligand modulation of the A<sub>2A</sub>R-H<sub>3</sub>R interaction in HEK-293 cells. Activation of the WT-H<sub>3</sub>R with its agonist RAMH led to functional complementation when co-expressed with the A<sub>2A</sub>R<sub>302</sub>-Gα<sub>qi4</sub> but not with A<sub>2A</sub>R<sub>302</sub>-Gα<sub>qs4</sub>. B. Ca<sup>2+</sup> mobilization was not observed when the WT-A<sub>2A</sub>R was co-transfected with the truncated H<sub>3</sub>R<sub>427</sub>-Gα<sub>qs4</sub> or H<sub>3</sub>R<sub>427</sub>-Gα<sub>qi4</sub>, in accord with the incapability of the receptor to activate the chimeric proteins. C. As shown in Figure 1D, activation of the H<sub>3</sub>R<sub>427</sub>-Gα<sub>qi4</sub> resulted in Ca<sup>2+</sup> mobilization, and this response was prevented when it was co-expressed with the WT-A<sub>2A</sub>R, suggesting a preference of the H<sub>3</sub>R<sub>427</sub>-Gα<sub>qi4</sub> to form heterodimers. D. The well-studied A<sub>2A</sub>R-D<sub>2</sub>R heterodimer was used as a positive control for these experiments. Activation of the D<sub>2</sub>R with increasing concentrations of the agonist quinpirole caused marked Ca<sup>2+</sup> mobilization only when co-expressed with the chimeric A<sub>2A</sub>R<sub>302</sub>-Gα<sub>qi4</sub>. E. The histamine H<sub>4</sub> receptor (H<sub>4</sub>R) as a negative control. No functional complementation was observed when the receptor was co-expressed with the A<sub>2A</sub>R<sub>302</sub>-Gα<sub>qi4</sub>, showing the specificity of the A<sub>2A</sub>R-H<sub>3</sub>R interaction. F. Functional complementation between the A<sub>2A</sub>R<sub>302</sub>-Gα<sub>qi4</sub> and the WT-H<sub>3</sub>R was not observed when the latter receptor was activated with the endogenous agonist histamine. For all graphs data are means ± SEM from 3 replicates from representative experiments. Where SEM bars are not visible, they are smaller than the symbol size. The quantitative analysis is shown in Table 1 and Supplementary Table 2.




**Figure 4.**

H<sub>3</sub>R activation enhances A<sub>2A</sub>R-mediated cAMP signaling in HEK-293 cells. A. Activation of the G<sub>α<sub>s</sub></sub>-coupled A<sub>2A</sub>R with its agonist CGS-21680 induced cAMP formation and H<sub>3</sub>R co-activation enhanced A<sub>2A</sub>R efficacy. Co-expression of the H<sub>3</sub>R did not modified the A<sub>2A</sub>R functional response. Values for pEC<sub>50</sub> and maximal effect (E<sub>max</sub>) are given in Table 2. B. H<sub>3</sub>R activation with RAMH decreased forskolin-induced cAMP formation in accord with the inhibitory nature of the G<sub>α<sub>i/o</sub></sub>-coupled receptor. A<sub>2A</sub>R expression and receptors co-activation lead to a change in the H<sub>3</sub>R signaling. Data are means ± SEM from 5 replicates from a representative experiments. Where SEM bars are not visible, they are smaller than the symbol size. Values for pIC<sub>50</sub> and maximal effect (I<sub>max</sub>) are given in Table 2.



**Figure 5.**

Co-immunoprecipitation of the A<sub>2A</sub> and H<sub>3</sub> receptors in striatal synaptosomes. A. The H<sub>3</sub>R co-immunoprecipitated with the A<sub>2A</sub>R in a protein extract of Percoll-purified striatal synaptosomes. The band of ~45 kDa corresponds to the expected migration of the H<sub>3</sub>R. No band was observed in the negative control ( $\alpha$ -CD81). B. Co-immunoprecipitation of the A<sub>2A</sub>R with the H<sub>3</sub>R in a protein extract of striatal synaptosomes. The band of ~45 kDa corresponds to the expected migration of the A<sub>2A</sub>R. The figure depicts representative blots, repeated a further 4 times with similar results. Full blots are shown in Supplementary Figure 6.

**Figure 6.**

H<sub>3</sub>R activation decreases A<sub>2A</sub>R affinity for the agonist CGS-21680 in synaptosomal membranes but not in membranes from the whole striatum. A. CGS-21680 (10 and 100 nM) did not modify the H<sub>3</sub>R affinity for its ligand RAMH in membranes isolated from striatal synaptosomes. B. In the same preparation, the H<sub>3</sub>R agonist RAMH (100 nM) decreased the A<sub>2A</sub>R affinity for [<sup>3</sup>H]-CGS-21680. Values are means ± SEM from 3 replicates from a representative experiment. C. Analysis of 3 independent experiments. The statistical analysis was performed with paired Student's *t* test. D. H<sub>3</sub>R activation with RAMH (100 nM) failed to decrease the A<sub>2A</sub>R affinity for [<sup>3</sup>H]-CGS-21680 in membranes from the whole striatum. Values are means ± SEM from 3 replicates from a representative experiment. Where SEM bars are not visible, they are smaller than the symbol size.

**Table 1.**

Pharmacological characteristics of the A<sub>2A</sub>R-H<sub>3</sub>R functional complementation assays in transfected HEK-293 cells

Transfection	Agonist	E <sub>max</sub> (%)	pEC <sub>50</sub>
H <sub>3</sub> R + Gα <sub>qi4</sub>	RAMH	419 ± 25	7.73 ± 0.31
	Histamine	504 ± 22 <sup>b</sup>	6.19 ± 0.17 <sup>b</sup>
H <sub>3</sub> R <sub>427</sub> -Gα <sub>qi4</sub>	RAMH	753 ± 41	7.14 ± 0.21
H <sub>3</sub> R <sub>427</sub> -Gα <sub>qi4</sub> + H <sub>3</sub> R	RAMH	523 ± 41 <sup>b</sup>	7.38 ± 0.34
A <sub>2A</sub> R <sub>302</sub> -Gα <sub>qi4</sub> + H <sub>3</sub> R	RAMH	449 ± 25	7.31 ± 0.23
	RAMH + CGS	429 ± 14 <sup>ns</sup>	7.63 ± 0.15
H <sub>4</sub> R + Gα <sub>qi4</sub>	Histamine	725 ± 51	6.35 ± 0.25
	RAMH	551 ± 27 <sup>a</sup>	6.15 ± 0.16
H <sub>2</sub> R + Gα <sub>qs4</sub>	Dimaprit	860 ± 37	6.15 ± 0.12
A <sub>2A</sub> R <sub>302</sub> -Gα <sub>qi4</sub> + D <sub>2</sub> R	Quinpirole	612 ± 34	6.47 ± 0.22

Data are means ± SEM from 3 experiments. Statistical comparisons were performed between two agonists for the same transfection, or between the transfection with the chimeric receptor and the transfection of the chimeric receptor plus the wild type receptor. ns, no significant difference

<sup>a</sup>*P* < 0.05

<sup>b</sup>*P* < 0.01, Student's *t* test.

Both RAMH and CGS-21680 were assayed at 100 nM. RAMH, R-α-methylhistamine; CGS, CGS-21680.

**Table 2.**

Pharmacological characteristics of the cAMP formation assay in transfected HEK-293 cells.

Transfection	Agonist	pEC <sub>50</sub>	E <sub>max</sub> (%)	pIC <sub>50</sub>	I <sub>max</sub> (%)
A <sub>2A</sub> R	CGS	8.0 ± 0.4	152 ± 7	-	-
A <sub>2A</sub> R + H <sub>3</sub> R	CGS	8.7 ± 0.5	153 ± 7	-	-
A <sub>2A</sub> R + H <sub>3</sub> R	+RAMH	8.0 ± 0.2	248 ± 9 <sup>b</sup>	-	-
H <sub>3</sub> R	RAMH	-	-	8.1 ± 0.3	-26 ± 2
H <sub>3</sub> R ± A <sub>2A</sub> R	RAMH	10.6 ± 1	114 ± 3	-	-
H <sub>3</sub> R ± A <sub>2A</sub> R	+CGS	9.9 ± 0.6	120 ± 2	-	-

Data are means ± SEM from 3 experiments. Statistical comparisons were performed between two agonists for the same transfection, or between the transfection with the chimeric receptor and the transfection of the chimeric receptor plus the wild type receptor. ns, no significant difference

<sup>a</sup>*P* < 0.05

<sup>b</sup>*P* < 0.01, Student's *t* test.

Both RAMH and CGS-21680 were assayed at 100 nM. RAMH, R-α-methylhistamine; CGS, CGS-21680.

**Table 3.**

Analysis of binding assays in rat striatal membranes

	<b>pKi</b>	<b>Bmax (%)</b>
<b>[<sup>3</sup>H]-NAMH</b>		
Synaptosomes		
RAMH	9.09 ± 0.22	100.0 ± 0.3
RAMH + CGS 10 nM	8.99 ± 0.02 <sup>ns</sup>	110.0 ± 4.0 <sup>ns</sup>
RAMH + CGS 100 nM	9.08 ± 0.06 <sup>ns</sup>	103.0 ± 4.1 <sup>ns</sup>
<b>[<sup>3</sup>H]CGS-21680</b>		
Whole striatum		
CGS	8.06 ± 0.15	100.0 ± 14
CGS + RAMH	8.11 ± 0.04 <sup>ns</sup>	88.0 ± 6.0 <sup>ns</sup>
Synaptosomes		
CGS	8.10 ± 0.04	100.0 ± 9.0
CGS + RAMH	7.70 ± 0.04 <sup>a</sup>	88.1 ± 10.0 <sup>ns</sup>

Data are means ± SEM from 3–5 experiments. For [<sup>3</sup>H]-NAMH binding assays the statistical analysis was performed with one-way Anova and Dunnett's *post hoc* test. For [<sup>3</sup>H]-CGS-21680 binding, values in the presence of RAMH were compared with the corresponding control with Student's *t* test.

<sup>a</sup>*P* < 0.001, ns, not significant. CGS, CGS-21680. RAMH (R-α-methylhistamine) was tested at 100 nM in all the experiments.